Life Sciences

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

  1. 30 Dec 2022  |  North America

    Trends and Growth Indicators for Physician Offices/labs in Decentralized Testing and Services

    Personalized Diagnostics Are at the Cusp of Transformational Growth

    Accelerated reforms due to COVID-19 and technologically advanced sample-in-answer-out portable, web-connected, encrypted devices that provide results in a few minutes changed the diagnostic healthcare industry. Decentralized testing empowers clinicians to make lifesaving decisions for the patient. It shortens supply chain lag time, saves costs of i...

    $2,450.00
  2. 30 Dec 2022  |  Global

    Growth Opportunities in Global Pharmaceutical Logistics

    Cold chain Investments and Hybrid Clinical Trials to Ensure Transformational Growth of Pharmaceutical Logistics

    Medicine production supply chains are currently operating under huge stress due to the war in Ukraine, COVID-19-related disruptions, logistics bottlenecks, and inflation. An energy-related shutdown of production would have a detrimental effect on the supply of critical medicines to patients in the EU and worldwide. The excessive amount of pressure ...

    $2,450.00
  3. 21 Dec 2022  |  Global

    Antibody-drug Conjugates: Technology Growth Opportunities

    Disruptive Technologies and a Conducive Funding Environment are Fostering Growth

    Antibody-drug conjugates (ADCs) are therapies that target cancer cells with antigen-specific antibodies and highly toxic payloads. ADCs are currently generating interest among drug developers, contract manufacturing companies, regulatory agencies, and other stakeholders. The rise in the number of drug approvals has also sparked interest in further ...

    $4,950.00
  4. 21 Dec 2022  |  North America

    Growth Opportunities and Innovative Use Cases for AI in Clinical Trials

    Integrating Real-world Insights into Intelligent Platforms to Enable Patient-centric Trial Design

    As clinical pipelines globally witness a surge in novel complex therapies, the clinical trial industry demands new tools in predictive analytics to improve trial design, planning, and execution. Artificial intelligence is gaining large-scale recognition as support for decentralized trial designs, thus enabling patient-centric clinical trial designs...

    $2,450.00
  5. 20 Dec 2022  |  Global

    Advances and Growth Opportunities in RNA Vaccines

    Technology Innovations and Investments Bolster Next-generation Prophylactic and Therapeutic RNA Vaccines

    RNA therapeutics and vaccines have been around for a long time, but the COVID-19 pandemic enabled their mass-market commercialization. Industry players saw mRNA vaccines developed for COVID-19 as effective for reducing the impact of the SARS-CoV-2 virus in populations. Moderna emerged as the first player to develop and commercialize an mRNA vaccine...

    $4,950.00
  6. 19 Dec 2022  |  North America

    PCR-based PoC Platforms for Infectious Disease Testing Growth Opportunities

    Multimodal and Multiplex Platforms are Expanding the Molecular PoC Testing Ecosystem

    Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

    $2,450.00
  7. An increasing focus on biologics, genomics, and multi-omics; the adoption of digital technologies; and a shift to patient-centric models are transforming the life sciences industry. At the same time, the emergence of value-based models, R&D activities to treat complex diseases, and healthcare consumerism provide an impetus to precision medicine. Wi...

    $2,450.00
  8. 01 Dec 2022  |  North America

    Global in Vitro Fertilization Services Growth Opportunities

    Disruptive Technologies and Innovative Business Models are the Key Drivers in the IVF Services Industry

    This study analyzes the in vitro fertility (IVF) services market across the globe. With infertility rates increasing across the world, assisted reproductive technologies (ART), including IVF, are gaining prominence. With technology advancements, the IVF process has undergone several modifications, with mainstream service providers such as fertility...

    $4,950.00
  9. 16 Nov 2022  |  North America

    Frost Radar™: Cell and Gene Therapy Contract Development and Manufacturing Organizations, 2022

    A Benchmarking System to Spark Companies to Action-Innovation that Fuels New Deal Flow and Growth Pipelines

    As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

    $4,950.00
  10. 11 Nov 2022  |  North America

    Global Contract Research Organization (CRO) Growth Opportunities

    Strong Competitive Intensity is Mandating a Greater Industry Convergence Resulting in a Strong Market Growth

    The COVID-19 pandemic led to a sudden surge in R&D activities across the world. Both small and large pharmaceutical and biotech companies were engaged in tremendous efforts to either develop new molecules or repurpose existing therapies as potential drugs for COVID-19 treatment. The trend is likely to continue with small-to-medium-segment and e...

    $4,950.00